Pfizer Inc.
Tissue-specific genome engineering using CRISPR-Cas9
Last updated:
Abstract:
The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
Status:
Grant
Type:
Utility
Filling date:
9 Nov 2016
Issue date:
1 Dec 2020